Group ACYW135 Meningococcal Polysaccharide Vaccine / Incepta Pharma, Walvax - LARVOL DELTA

A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years (clinicaltrials.gov) - P4; N=260; Completed; Sponsor: Walvax Biotechnology Co., Ltd.; Recruiting ➔ Completed; Trial completion date: Apr 2021 ➔ Jul 2021; Trial primary completion date: Apr 2021 ➔ Jul 2021

Clinical • Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Infectious Disease

A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years (clinicaltrials.gov) - P4; N=260; Recruiting; Sponsor: Walvax Biotechnology Co., Ltd.; Not yet recruiting ➔ Recruiting; Initiation date: Jun 2020 ➔ Dec 2020

Clinical • Enrollment open • Trial initiation date • CNS Disorders • Infectious Disease

A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years (clinicaltrials.gov) - P4; N=260; Not yet recruiting; Sponsor: Walvax Biotechnology Co., Ltd.

Clinical • New P4 trial • Infectious Disease